Impact of early antiretroviral treatment on sexual behaviour in the INSIGHT Strategic Timing of Anti-Retroviral Treatment (START) Trial

Citation for published version:
INSIGHT START Study Group 2019, 'Impact of early antiretroviral treatment on sexual behaviour in the INSIGHT Strategic Timing of Anti-Retroviral Treatment (START) Trial', AIDS. https://doi.org/10.1097/QAD.0000000000002359

Digital Object Identifier (DOI):
10.1097/QAD.0000000000002359

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
AIDS

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Impact of early antiretroviral treatment on sexual behaviour in the INSIGHT Strategic Timing of Anti-Retroviral Treatment (START) Trial

Short title: Early ART and sexual behaviour in the START trial

Authors
Fiona C Lampe¹, Alison J Rodger¹, William Burman², Andrew Grulich³, Gerald Friedland⁴, Wafaa El Sadr⁵, James Neaton⁶, Giulio M. Corbelli⁷, Sean Emery³, Jean Michel Molina⁸, Chloe Orkin⁹, Jose Gatell¹⁰, Jan Gerstoft¹¹, Kiat Ruxrunatham¹², Monica Barbosa de Souza¹³*, Andrew Phillips¹ for the INSIGHT START Study Group

Affiliations
1. Institute for Global Health, University College London, London, United Kingdom
2. Denver Public Health, University of Colorado Health Sciences Center, Denver CO, United States
3. The Kirby Institute, University of New South Wales, Sydney, Australia
4. Departments of Medicine and Epidemiology, Yale School of Medicine, New Haven CT United States
5. Columbia University, New York, United States
6. University of Minnesota, Minnesota, United States
7. European AIDS Treatment Group, Bruxelles, Belgium
8. Université de Paris Diderot, Paris, France
9. Barts Health NHS Trust, London, United Kingdom
10. University of Barcelona, Barcelona, Spain
11. Copenhagen University Hospital, Copenhagen, Denmark
12. Chulalongkorn University, Bangkok, Thailand
13. Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

* Deceased

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
Dr Fiona Lampe, Institute for Global Health, University College London (UCL), Royal Free Campus, Rowland Hill Street. London, NW3 2PF. Email: f.lampe@ucl.ac.uk
Abstract

**Background:** Antiretroviral treatment (ART) reduces HIV infectiousness, but the effect of early ART on sexual behaviour is unclear.

**Methods:** We assessed, within the START randomised trial that enrolled HIV-positive adults with CD4>500/mm³, the effect of early (immediate) versus deferred ART on: (i) condomless sex with HIV-serodifferent partners (CLS-D); (ii) all condomless sex (CLS); (iii) HIV transmission-risk-sex (CLS-D-HIV-risk, defined as CLS-D and: not on ART or started ART <6 months ago or viral load(VL)>200c/mL or no VL in past 6 months), during two year follow-up. Month-12 CLS-D (2010-2014) was the primary outcome.

**Results:** Among 2562 MSM, there was no difference between immediate and deferred arms in CLS-D at month 12 [12.6% versus 13.1%; difference (95% CI):-0.4%(-3.1%, 2.2%),p=0.75] or month 24, or in CLS. Among 2010 heterosexual men and women, CLS-D at month 12 tended to be higher in the immediate versus deferred arm [10.8% versus 8.3%; difference:2.5%(-0.1%, 5.2%),p=0.062]; the difference was greater at month 24 [9.3% versus 5.6%; difference:3.7%(1.0%, 6.4%),p=0.007], at which time CLS was higher in the immediate arm [20.7% versus 15.7%,p=0.013]. CLS-D-HIV-risk at month 12 was substantially lower in the immediate versus deferred arm for MSM [0.2% versus 11.0%; difference:-10.7%(-12.5%, -8.9%),p<0.001] and heterosexuals [0.6% versus 7.7%; difference:-7.0%(-8.8%, -5.3%),p<0.001], due to viral suppression on ART.

**Conclusions:** A strategy of early ART had no effect on condomless sex with HIV-serodifferent partners among MSM, but resulted in modestly higher prevalence among heterosexuals. However, among MSM and heterosexuals, early ART resulted in a substantial reduction in HIV-transmission-risk-sex, to a very low absolute level.

Key words: HIV; ART; condomless sex; transmission; MSM; heterosexual
**Introduction**

In 2015, results were published from the START (Strategic Timing of Antiretroviral Treatment Trial)\(^1\,^2\) and TEMPRANO\(^3\) randomised trials, demonstrating that a strategy of immediate ART (regardless of CD4 cell count) for people with diagnosed HIV reduced serious morbidity and mortality compared to ART deferral. Guidelines that had previously set CD4 thresholds for ART initiation were changed to recommend ART initiation for all adults with HIV at any CD4 level.\(^4\,^5\) US guidelines had already recommended such a strategy, primarily based on evidence from observational studies.\(^7\)

Prior to this conclusive evidence of the clinical benefit of early ART, results had been accumulating regarding the protective effect of ART on HIV transmission. Initially, a number of observational studies demonstrated a marked association between the viral load (VL) of an HIV-positive person and the risk of HIV transmission to an HIV-negative partner.\(^8\,^12\) In 2011, unequivocal evidence came from the HPTN 052 randomised trial, which demonstrated that use of early ART for the HIV-positive partner of serodifferent couples was associated with a 96% reduction in transmissions to the HIV-negative partner.\(^13\) Subsequently, the PARTNER\(^14\), PARTNER2\(^15\) and Opposites Attract\(^16\) prospective observational studies provided crucial information on transmission risk specifically through condomless sex (CLS), including anal CLS, among HIV serodifferent heterosexual and MSM couples. In each of these studies, there were no within-couple linked HIV transmissions during eligible follow-up in which couples reported CLS and the HIV-positive partner was virally suppressed on ART. Together these studies have provided the necessary evidence for assurance that HIV-positive people on ART with undetectable VL cannot transmit HIV (Undetectable=Untransmittable; Prevention Access Campaign).\(^17\)
As knowledge regarding the protective effect of VL suppression on HIV infectiousness has been disseminated and publicized, and in particular since the ‘Swiss Statement’ in 2008, it has been debated whether such knowledge impacts on sexual behaviour and patterns of condom use among people taking ART. Initially the concern was that if viral suppression on ART led merely to a reduction in (rather than elimination of) HIV transmission risk, any increase by the HIV-positive individual in CLS with HIV-serodifferent partners (CLS-D) could partially negate the benefit of ART. Recent findings have provided reassurance on this point, demonstrating no transmission risk in this context. However an increase in CLS-D associated with ART use may still be concerning in the context of sub-optimal ART adherence, infrequent VL monitoring, inaccurate knowledge of personal VL status or poor knowledge of the importance of viral suppression, a key issue in early treatment. Furthermore, any changes in patterns of CLS overall may have implications for transmission of other sexually transmitted infections (STIs). It is also conceivable that reductions in condom use among HIV-positive people may affect condom use among HIV-negative people with partners of unknown HIV status.

There is, to date, little compelling evidence that ART use leads to higher levels of condomless sex among people with HIV. Findings from some observational studies have suggested that, in some contexts or subgroups, condom use may be influenced by knowledge of viral suppression. However, in most studies, overall, levels of CLS-D were similar or lower among people on ART compared to those not on ART (or among people with undetectable compared to detectable VL). Two randomised trials have provided data on this issue; neither supports the hypothesis that ART use leads to increased CLS-D. However, it is important to reevaluate this association as patterns of sexual behaviour may have changed with increasing awareness of the protective effect of suppressed VL,
particularly since publication of HPTN 052 in 2011. Furthermore, now that the protective effect of viral suppression on HIV transmission is assured, it is necessary to consider measures additional to CLS-D, that capture sex with risk of HIV-transmission by accounting for viral suppression. When considering risk of other STIs, CLS overall is the most relevant measure.

We previously reported on sexual behaviour at enrolment in the START trial. We now assess, separately among MSM and heterosexual individuals, the effect of a strategy of early ART compared to ART deferral on sexual behaviour in the first two years of follow-up, considering: CLS-D at month 12 (the pre-defined primary outcome), CLS, CLS-D with risk of HIV transmission, and other measures.

**Methods**

**Study population**

START was an open-label multicenter randomized trial enrolling 4684 HIV-positive people who had never taken ART and who had a CD4 count above 500 cells/µL, from April 2009 to December 2013. Individuals were randomised to either start ART immediately (early ART) or to defer ART until occurrence of a CD4 cell count below 350 cells/µL or an AIDS event. The primary endpoint was serious AIDS or non-AIDS morbidity or mortality. On May 15th 2015, the Data and Safety Monitoring Board determined that the study question had been answered and recommended that ART be offered to all participants. Rate of the primary endpoint was lower in the immediate versus deferral arm [hazard ratio (95% CI): 0.43 (0.30, 0.62) p<0.001].

**Transmission risk behaviour study**

Participants were asked to self-complete a transmission risk behaviour questionnaire at baseline, month 4, and every 12 months subsequently. Sexual activity (vaginal or anal sex) during the previous 2 months was ascertained for: men having sex with women; men having
sex with men; women having sex with men. All participants who had a risk behaviour questionnaire available within the first two years (at 4, 12, or 24 months) were included in this analysis. All information provided after 15th May 2015 was excluded. Sexual behaviour measures (two month recall period) were derived at baseline and each follow-up point, including: (i) condomless sex with HIV-serodifferent (negative or unknown status) partners(s) (CLS-D); (ii) condomless sex (CLS); (iii) HIV transmission risk sex (CLS-D-HIV-risk) defined as CLS-D plus at least one of: not on ART; started ART <6 months ago; most recent VL>200c/mL; no VL in last 6 months. This last measure was intended to capture sex with a risk of HIV transmission. If a person having CLS-D was on ART, having started ART at least 6 months ago, and had most recent VL (measured within the past 6 months) ≤200 c/mL, then risk was assumed to be zero. Additional measures included: ≥2 CLS partners; ≥3 CLS partners; ≥2 CLS-D partners; ≥3 CLS-D partners; ≥2 times CLS-D; ≥10 times CLS-D; insertive CLS-D with ejaculation (men only); total number of CLS-D acts (see Table 3 footnote for details). Injection drug use transmission risk was defined as having injected drugs in the past two months and having shared needles or other equipment with someone who had negative/unknown HIV status. Transmission risk beliefs were beliefs related to whether a person using HIV treatment who had an undetectable viral load could pass on HIV to another person through unprotected sex. Responses of: “cannot” and “much less likely” were grouped together in contrast to: “a little less likely”, “just as likely” and “more likely”. The pre-specified primary outcome was CLS-D at month 12. Separate analyses were pre-specified for MSM, and heterosexual men and women (combined). Some measures were considered only for MSM, due to low frequency among heterosexual participants.
Transmission risk behavior forms were updated early in recruitment. Information on CLS-D and CLS-D-HIV-risk was available from original and updated forms; information on all other outcomes was available only from the updated version. Participants were included in an analysis at a specific time point if the relevant behaviour questionnaire was available; treatment of missing values is described in the footnote of Table 3.

**Statistical methods**

Baseline characteristics, and ART use and viral suppression over follow-up, were summarised according to gender/sexual orientation. Subsequent analyses were carried out separately for: MSM; heterosexual men and women combined. Sexual behaviour and attitude measures were summarised by time point and randomised arm. An alternative baseline measure excluded participants diagnosed with HIV for less than three months who may have been reporting pre-diagnosis sexual behaviour. Chi-squared tests were used to compare proportions between randomised arms at months 4, 12 and 24; Mann-Whitney U tests were used to compare number of CLS-D acts among the subgroup of participants who were diagnosed >3 months ago and reported CLS-D at baseline. Logistic regression was used to obtain odds ratios for the intervention effect on CLS-D prevalence at month 12: unadjusted, adjusted for baseline factors, and stratified by baseline factors. Factors considered were: gender (heterosexual analysis only); age group (<40; ≥40 years); recruitment setting (low/middle income [Africa, Asia, Central/South America]; high income [Europe/Israel; North America; Oceania]; date randomised (<2012; ≥2012); time since HIV diagnosis (<0.5 years; ≥0.5 years); education level (less than high school; high school or above). Interaction tests were used to assess whether the intervention effect differed across subgroups.
In addition, a generalized estimating equation (GEE) logistic model was used in which data from months 4, 12 and 24 were combined, with CLS-D as the dependent variable, and time point (month 4, 12, 24), randomization arm (immediate; deferred), calendar year (year of completion of risk questionnaire, as an ordinal measure) and gender (heterosexual model only) as independent variables. An autoregressive correlation structure was used to account for repeated responses from individuals. Interaction terms between randomised arm and time point were assessed.

For all comparisons participants were kept in their original randomised group.

**Results**

Of the 4684 HIV-positive people who were randomised, 112 (2.4%) were excluded from analysis as they had not completed a transmission risk questionnaire during the two year follow-up. Of the remaining 4572 participants there were 2562 MSM, 788 heterosexual men, and 1222 women. Baseline characteristics are shown in Table 1.

*Sexual behaviour at baseline*

The baseline transmission risk questionnaire was completed by 4504 of 4572 (98.5%) participants (original version N=547, updated version N=3957). Prevalence of CLS in the past two months was 39.2%, 23.8%, and 28.1% among MSM, heterosexual men and women respectively; prevalence of CLS-D was 19.9%, 9.6% and 14.5% respectively. CLS-D-HIV-risk prevalence was identical to CLS-D prevalence (by definition, as no participants were on ART at baseline).

*ART use and viral suppression over time*

As of May 15 2015, of 4572 participants, all should have attended the months 4 and 12 visits, and 3673 (80.3%) should have attended the month 24 visit. Table 2 shows numbers
completing the risk behaviour questionnaire by time point and the prevalence of ART use and VL ≤200 copies/mL, according to randomised arm and gender/sexual orientation. In the immediate arm, the proportion of participants who were on ART remained fairly stable from month 4 to month 24, at around 96-98%. Correspondingly, the prevalence of VL ≤200 copies/mL increased rapidly from baseline to month 4, with some further increase to month 24. In the deferred arm, the proportion on ART increased steadily over follow-up (as more individuals reached eligibility for ART initiation), mirrored by an increase in prevalence of viral suppression.

**Comparison of sexual behaviour at month 12 between randomised arms**

Table 3 shows sexual behaviour by randomised arm and time point for: (A) MSM and (B) heterosexual men and women.

Among MSM, prevalence of CLS-D at month 12 (the primary outcome) was similar in the immediate and deferred arms: 12.6% versus 13.1% [difference: -0.4%, 95% CI (-3.1%, 2.2%), p=0.75 Chi-squared test]. The prevalence of CLS, ≥2 CLS-D partners, ≥3 CLS-D partners, ≥2 times CLS-D, >10 times CLS-D and insertive CLS-D with ejaculation at month 12 did not differ between the arms, nor did number of CLS-D acts among the subgroup diagnosed >3 months ago who reported CLS-D at baseline. The prevalence of CLS-D-HIV-risk at month 12 among MSM was much lower in the immediate versus deferred arms: 0.2% versus 11.0% [difference: -10.7%, 95% CI (-12.5%, -8.9%), p>0.001], due to the far higher prevalence of VL suppression on ART in the immediate arm.

Among heterosexual men and women there was some evidence that CLS-D at month 12 was higher in the immediate versus deferred arm: 10.8% versus 8.3% [difference: 2.5% 95% CI (-
A similar pattern was apparent for ≥2 times CLS-D: 7.1% versus 5.2%, [difference: 1.9%, 95% CI (=0.3%, 4.1%), p=0.089, Chi-squared test].

Prevalence of CLS, ≥2 CLS partners, ≥2 CLS-D partners, and insertive CLS-D with ejaculation did not differ by arm at month 12, nor did number of CLS-D acts among those diagnosed >3 months ago who reported CLS-D at baseline. Although prevalence of CLS-D was somewhat higher in the immediate versus deferred arm among heterosexual individuals, the prevalence of CLS-D-HIV-risk at month 12 was much lower in the immediate arm: 0.6% vs 7.7% [difference:-7.0%, 95% CI (-8.8%, -5.3%), p<0.001, Chi-squared test], due to viral suppression on ART.

**Comparison of randomised arms according to baseline factors: CLS-D at month 12**

The odds ratio (95% CI) of CLS-D at month 12 for the immediate versus deferred strategy was 0.96 (0.76, 1.22) for MSM and 1.34 (0.98, 1.82) for heterosexual men and women (the latter adjusted for gender). (Figure 1). Among MSM, there was no evidence that the intervention effect on CLS-D varied across subgroups. Among heterosexual men and women, the intervention effect (higher CLS-D at month 12 in the immediate versus deferred arm) was greater among participants aged <40 years (p=0.035 for interaction).

**Time since randomisation and sexual behaviour**

Table 3 and Figure 2 show the prevalence of sexual behaviour measures by time point and randomised arm. The additional baseline estimates exclude participants diagnosed for less than three months.

Prevalence of CLS-D fell from revised baseline to month 4 in both arms, among MSM and heterosexuals. By month 24, prevalence had increased back towards the revised baseline level.
for MSM in both arms, and for heterosexuals in the immediate arm. For heterosexuals in the deferred arm, prevalence of CLS-D continued to fall throughout follow-up, resulting in higher CLS-D prevalence in the immediate versus deferred arm at month 24 [9.3% vs 5.6%, difference: 3.7%, 95% CI (1.0%, 6.4%), p=0.007, Chi-squared test].

Patterns in CLS-D prevalence during follow-up were assessed formally in two multivariable logistic GEE models using data from the 4, 12 and 24 month time points. Among MSM (N=7003 observations), there was no interaction between randomised arm and study time point (p=0.24). In a model without an interaction term, CLS-D did not differ by randomised arm [aOR immediate vs deferred: 1.00 (0.84, 1.19) p=0.99] or calendar year [aOR per later year: 0.99 (0.91, 1.07) p=0.76] but differed by study time point: compared to month 4, odds of CLS-D was similar at month 12 [adjusted odds ratio (aOR) (95% CI): 1.05 (0.91, 1.21)] but higher at month 24 [aOR: 1.32 (1.10, 1.58)], global p=0.002. Among heterosexual men and women (N=5330 observations), the effect of randomised arm on CLS-D differed according to time point (p=0.017 for interaction). In a model including the interaction term, the effect of immediate versus deferred arm on CLS-D became greater with time: aOR (95% CI): 0.91 (0.66, 1.26), 1.36 (1.00, 1.85) and 1.66 (1.13, 2.43) for months 4, 12 and 24 respectively. CLS-D did not differ with calendar year [aOR per later year: 1.05 (0.92, 1.18) p=0.48] but was higher for women compared to men [aOR (95% CI): 1.49 (1.15, 1.92) p=0.004].

Similar patterns over time were apparent when CLS was considered (Table 3 and Figure 1b). Prevalence of CLS-D-HIV-risk decreased over time from month 4, as participants started ART (Table 3 and Figure 1c). As expected this decrease was particularly dramatic in the
immediate ART group, resulting in substantial differences in CLS-D-HIV risk between randomised groups at months 12 and 24.

Transmission risk beliefs

At month 12, participants in the immediate arm were more likely than those in the deferred arm to indicate a belief that a person on HIV treatment with undetectable VL cannot, or is much less likely, to transmit HIV when having unprotected sex: 48.1% versus 40.4% for MSM [difference: 7.7%, 95% CI (-3.7%, 11.8%), p<0.001, Chi-squared test] and 36.7% versus 32.2% for heterosexuals [difference: 4.5%, 95% CI (0.03%, 8.9%), p=0.049] (Table 3). Similar differences between arms were apparent at month 24 (Table 3).

For both MSM and heterosexuals, the proportion of participants who indicated this belief in a strong protective effect of viral suppression tended to increase over time from baseline in both arms. However evidence that this belief was more likely with later calendar time was relatively weak. There was no trend in proportions reporting this belief over calendar time of questionnaire completion among MSM or heterosexuals in the immediate arm at month 12 or 24. In the deferred arm, there was some evidence of a trend at month 24: percentages of MSM reporting this belief were 43.8%, 44.1%, 47.4%, 57.1% for month 24 completion years 2012-12, 2013, 2014 and 2015 respectively (p=0.019 for trend). The corresponding percentages for heterosexuals were 26.8%, 39.8%, 43.9%, 36.5% (p=0.058 for trend).

Transmission risk beliefs varied across regions. MSM recruited from high income settings were more likely than those from low/middle income settings to indicate belief in a strong protective effect of viral suppression [53.6% versus 30.7% at month 12, p<0.001; 58.3% versus 36.2% at month 24, p<0.001]. However the opposite was true for heterosexuals at
month 12 [30.1% for high income versus 35.8% for low/middle income at month 12, p=0.029] with no difference at month 24 [41.7% versus 41.1%, p=0.84].

**Risk behaviour related to injection drug use**

At baseline, 1.9% of MSM (40/2147) and 0.8% (15/1810) of heterosexual participants reported injecting recreational drugs in the past two months, of whom only three and four individuals respectively reported injection drug use transmission risk. At month 12, 2.0% of MSM (48/2355) reported injection drug use: 1.6% in the immediate arm and 2.5% in the deferred arm, of whom two and one respectively reported injection drug use transmission risk. For heterosexual individuals, 0.4% (7/1846) reported injection drug use at month 12, 0.7% and 0.1% in the immediate and deferred arms respectively, of whom one and zero respectively reported injection drug use transmission risk.

**Discussion**

Among MSM, compared to ART deferral until a CD4<350 cells/μL or AIDS, a strategy of immediate ART had no impact on prevalence of HIV-serodifferent condomless sex (CLS-D) over the subsequent two years, or on related measures of frequency of such sex or partner numbers. Among heterosexual men and women, the immediate ART strategy resulted in modestly higher prevalence and frequency of HIV-serodifferent condomless sex at 12 and 24 months compared to deferred ART. Among both groups, the immediate ART strategy resulted in a substantial reduction in prevalence of HIV-transmission risk sex by month 12, as the vast majority of participants in this arm had viral suppression on ART and were therefore classified as no risk for HIV transmission, regardless of sexual behaviour.

CLS-D was the pre-defined primary endpoint in this study; this endpoint remains important
for understanding the impact of early ART on condom use with serodifferent partners. However, the two additional endpoints are the most relevant for HIV and STI transmission. CLS-D-HIV-risk best captures HIV transmission-risk sex by accounting for viral suppression on ART, now known to be a critical factor in preventing transmission. CLS best captures risk of transmission or acquisition of other STIs, for which HIV-serostatus of partners, ART and HIV viral load are not relevant. These results illustrate the profound impact of early ART on HIV-transmission risk sex, which was less than 1% in the immediate ART arm by month 12 (compared to 11% and 8% for MSM and heterosexuals respectively in the deferred ART arm) and was continued at this low level to month 24. Even though the immediate ART strategy resulted in a small increase in CLS-D among heterosexual participants at months 12 and 24, the impact of this was far outweighed by the high levels of viral suppression in this arm, which protected against HIV-transmission regardless of CLS-D. Even a very substantial increase in CLS-D would not have overturned the benefit conferred by early ART. Of note, this analysis suggested a benefit only from month 12, because the definition of CLS-D-HIV-risk required ART to have been started at least 6 months previously to confer protection from transmission. This was based on data from the Partners Prep study which indicated a reduced but residual transmission risk persisting during the first 6 months of ART, due to incomplete viral suppression in blood and genital compartments. In practice, and with newer ART drugs, viral suppression and subsequent protection may be attained at an earlier stage after ART initiation. But also of note, the difference between arms in CLS-D-HIV-risk attenuated from month 12 to month 24, and this would continue to occur as more individuals in the deferral arm started ART. In terms of STI transmission risk, the strategy of early ART resulted in a modest increase in prevalence of CLS among heterosexual individuals at year two only. However, less than 2% of heterosexual participants reported more than one CLS partner in the recall period. Risk of STI acquisition and transmission may be less concerning
in this context. Incidence of bacterial STIs was not assessed in START.

Two previous randomised trials have assessed the impact of ART on sexual transmission risk;\textsuperscript{47,48} neither supported the hypothesis that ART use leads to increased condomless sex. In the SMART trial (2002-2006), the prevalence of ‘high-risk behaviour’ (CLS-D or injecting risk behaviour) was similar compared between the continuous ART and CD4-guided episodic ART arms.\textsuperscript{47} Among the subgroup who were not on ART at baseline, there was a reduction in high-risk behaviour in the first two years in the continuous compared to episodic ART arm. More recently, in the TEMPRANO-ANRS12136 trial of immediate versus deferred ART initiation (2008-2012), the proportion of participants reporting CLS-D was similar when compared between randomised arms at year one.\textsuperscript{48} Many observational studies have assessed the association between ART and sexual behaviour among people with diagnosed HIV,\textsuperscript{24-46} including two meta-analyses\textsuperscript{29,32} and some studies in low/middle income countries.\textsuperscript{41,43,45} The vast majority found no association of ART use or viral suppression with CLS-D, or found ART was in fact associated with lower levels of CLS-D. A few studies reported different findings overall, or in specific subgroups or analyses. Among sexually active women in the US Women’s Interagency HIV Study (1996-2001), consistent condom use was less likely to be reported after ART initiation compared to pre-ART, in some adjusted models.\textsuperscript{24} A small Australian study of HIV-serodifferent MSM couples (2001-2003) found higher levels of anal CLS-D among couples for whom the positive partner had suppressed VL.\textsuperscript{25} The Swiss HIV Cohort Study (2007-2009) found evidence of higher levels of CLS-D with stable partners among participants who were virally suppressed compared to those not on ART.\textsuperscript{26} In a French study (2000-2009), in more recent years, ART use and suppressed VL were associated with CLS-D among HIV-diagnosed heterosexual men with steady partners.\textsuperscript{27} In the UK ASTRA study (2011-12), prevalence of CLS-D among MSM on ART was higher for those with self-
reported undetectable VL compared to those without.\textsuperscript{28} Finally, a subsidiary analysis in one of the aforementioned meta-analyses found that an undetectable VL was associated with slightly higher sexual risk-taking.\textsuperscript{29}

Therefore previous literature suggested that, in some contexts, condom use may be influenced by knowledge of viral suppression, but the effect may be modest, and evidence is relatively weak in light of all relevant studies. These current results from START are the most contemporary (2010-2015) but seem broadly consistent with this synopsis, showing that starting ART may have modestly reduced condom use among heterosexuals. Although the combined heterosexual group was the predefined population of analysis, the pattern of results was broadly similar when men and women were examined separately (data not shown). The results from START and the other randomised trials have advantage that confounding is minimized in the comparison of the groups randomised to start or defer ART. It should also be noted that, as in the TEMPRANO trial, this START analysis addresses a slightly different question to the observational studies, as it evaluates the impact of starting ART on sexual behaviour over two years among people with high CD4 counts. In most of the observational comparisons, people on ART varied in terms of time since starting treatment and CD4 count; conceivably impact on sexual activity and condom use may vary according to these factors. However in START there was no evidence that the intervention effect on CLS-D varied according to time since diagnosis in heterosexual individuals or MSM.

There may be a number of reasons why, in START, the effect of early ART on CLS-D was apparent only in the heterosexual group. Patterns of partnerships differed for heterosexuals compared to MSM, with the vast majority having only one condomless sex partner during the recall periods. Possibly trial participants were more likely to be given advice about the
protection from transmission conferred by viral suppression in the context of stable sero-
different relationships. Some advice may have been related to desire for conception, resulting in higher CLS-D among heterosexual participants on ART, and may in part explain why the intervention effect on CLS-D was greater among those aged under 40 years. Furthermore, the month 12 time point was during or after 2011 but before 2014 for the majority of participants, giving potential for awareness of results from HPTN 052 related to heterosexual transmission, but not for substantive evidence relating to MSM (results from PARNER, Opposites Attract and PARNTER2 first being presented in 2014-2018). However even at year two of follow-up, only about half of MSM and less than half of heterosexuals expressed belief in any substantial level of protection conferred by viral suppression; this is consistent with findings from other quantitative\textsuperscript{28} and qualitative\textsuperscript{21} studies. Although, in START, there was some evidence of increasing proportions expressing this belief over calendar time, trends were not marked or consistent across trial arms. Advice and information given to participants regarding viral suppression and transmission risks may also have differed across countries and clinical sites. Indeed there was evidence of significant variation in transmission risk beliefs by recruitment setting, which differed for MSM and heterosexuals. MSM from high income countries were more likely than those from low/middle income countries to express belief in a strong protective effect of viral suppression, whereas for heterosexuals there was some evidence of the opposite effect (belief more prevalent in low/middle income settings). The trial was carried out over a period of considerable change with regard to scientific evidence available on this issue, and publicity surrounding it, and these complex trends are likely to reflect this. Increasing emphasis on the “U=U” message\textsuperscript{17} may be leading to further changes in transmission risk beliefs and patterns of condom use; it is likely that the full effect of the current research evidence is yet to be apparent.
Among MSM, in both the immediate and deferred treatment arms, CLS-D prevalence fell from randomization to months 4 and 12, and subsequently increased back towards the revised baseline levels by year two. Among heterosexual participants, a similar but less marked decline in CLS-D occurred from revised baseline to month 4. Other studies have reported on temporary reductions in sexual risk for MSM following HIV diagnosis, and so a similar pattern may have occurred for those individuals in START who were newly diagnosed at trial entry. In addition, for all participants, trial participation and regular contact with health care professionals and services, may have had a moderating effect on levels of condomless sex.

Limitations of this study include the possibility of error or bias arising from self-reported sexual behaviour and incomplete or missing questionnaires, though 12 month response rates were high and similar between randomised arms, and questionnaires were self-completed. Participation in a trial with repeated monitoring of behavioural outcomes may have influenced condom use or it’s reporting. The measure of HIV-transmission risk sex assumes that the latest VL is applicable to the entire two-month recall period.

In conclusion, a strategy of early ART did not impact on levels of serodifferent condomless sex among MSM and resulted in a small increase among heterosexual individuals. However in both groups, the strategy had a substantial favourable impact on HIV transmission risk behaviour at one year and is therefore likely to result in a marked reduction in new HIV infections in the initial period. The modest increase in condomless sex among the heterosexual group suggests the importance of continuing to monitor sexual behaviour as ART use expands, in order to understand any impact on other sexually transmitted infections. Patterns of condomless sex may have changed with increasing promotion of the U=U message since the START trial was conducted.
Acknowledgements

We would like to thank the START participants without whom this work would not be possible.

For a complete list of START investigators see N Engl J Med 2015; 373: 795-807

The START study is registered at clinicaltrials.gov (NCT00867048).

Author contributions

FCL; AJR; WB; AG; GF; WES; JN; SE; AP contributed to questionnaire design and conceptualisation of the analysis. FL performed the analysis and drafted the manuscript. All authors contributed to data interpretation and revision of the manuscript. GMO; JMM; CO; JGa; JGe; KR; MBdS were clinical site principle investigators for the STRAT trial; SE was the regional co-ordinator; JN was the INSIGHT Primary Investigator.

Funding

The START study was primarily funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award numbers: UM1-AI068641 and UM1-AI120197. START was supported by the National Institutes of Health Clinical Center, National Cancer Institute, National Heart, Lung, and Blood Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (France), National Health and Medical Research Council (Australia), National Research Foundation (Denmark), Bundes ministerium für Bildung und Forschung (Germany), European AIDS Treatment Network, Medical Research Council (United Kingdom), National Institute for Health Research, National Health Service (United
Kingdom), and University of Minnesota. Antiretroviral drugs were donated to the central drug repository by AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen Scientific Affairs, and Merck.
References

1. Babiker AG, Emery S, Fatkenheuer G, et al. Considerations in the rationale, design and methods of the Strategic Timing of Antiretroviral Treatment (START) study. *Clin Trials* 2013; 10: Suppl: S5-S36

2. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. *N Engl J Med* 2015; 373:795-807

3. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D et al. Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. *N Engl J Med* 2015; 373:808-22

4. World Health Organization (WHO). Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. September 2015. www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/

5. European AIDS Clinical Society (EACS) guidelines for clinical management and treatment of HIV positive persons. 2015. http://www.eacsociety.org/files/2015_eacsguidelines_8_0-english_rev-20160124.pdf.

6. British HIV Association (BHIVA) guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy. 2015. http://www.bhiva.org/HIV-1-treatment-guidelines.aspx.

7. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2012, http://aidsinfo.nih.gov/guidelines.

8. Quinn TC, Wawer MD, Sewankambo N, et al. Viral load and heterosexual transmission of HIV type 1. *N Engl J Med* 2000; 342:921–929.
9. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. *AIDS Res Hum Retroviruses* 2001; 17: 901-910

10. Tovanbutra S, Robinson V, Wongtrakul J et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. *J Acquir Immune Defic Syndr* 2002; 29: 275-283

11. Attia S, Egger M, Muller M, Zwahlen M, Low M. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. *AIDS* 2009; 23: 1397-1404

12. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. *Lancet* 2010; 375:2092–2098.

13. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med* 2011; 365:493–505.

14. Rodger AJ, Cambiano V, Bruun T et al for the PARTNER Study Group. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. *JAMA*. 2016; 316:171-81.

15. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloikas A, Raben D, Coll P, Antinori A, Nwokolo N, Rieger A, Prins JM, Blaxhult A, Weber R, Van Eeden A, Brockmeyer NH, Clarke A, Del Romero J, Raffi F, Bogner J, Wandeler G, Gerstoft J, Gutierrez F, Brinkmann K, Kitchen M, Osstergaard L, Leon A, Ristola M, Jessen H, Stellbrinng H, Phillips AN, Lundgren L for the PARTNER Study Group. *In submission*

16. Bavinton B, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GB, Zablotska-Manos I, Jin F, Fairley CK, Moore R, Roth N, Bloh M, Pell C, McNulty AM, Baker D, Hoy J,
Tee BK, Templeton DJ, Cooper DA, Emery S, Kelleher A, Grulich AE for the Opposites Attract Study Group. Viral suppression and HIV transmission in homosexual male serodiscordant couples: an international cohort study. Lancet HIV 2018; 5: e438-e447

17. U=U Taking off in 2017. Lancet HIV 2017; 4: e475

18. Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes séropositives ne souffrant d’aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle. Bull des Medecins Suisses 2008; 89: 165-169

19. Wilson DP, Law MG, Grulich AW, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008; 372: 314-320

20. Vernazza P. The debate continues: does ‘undetectable’ mean ‘uninfectious’? HIV Therapy 2009; 3: 113-116

21. Persson A. Reflections on the Swiss Consensus statement in the context of qualitative interviews with heterosexuals living with HIV. AIDS Care 2010; 22: 1487-1492

22. Sewell J, Daskalopoulou M, Nakagawa F, Lampe FC, Edwards S et al. Accuracy of self-report of HIV viral load among people with HIV on antiretroviral treatment. HIV Med 2017; 18: 463-473

23. Mujugira A, Celum C, Coombs RW, Campbell JD, Ndase P, Ronald A, Were E, Bukusi EA, Mugo N, Kiarie J, Baeten JM; Partners PrEP Study Team. HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2016; 72: 579-84.

24. Wilson TE, Gore ME, Greenblatt R, et al. Changes in sexual behavior among HIV-infected women after initiation of HAART. Am J Public Health 2004; 94:1141–1146.

25. Van de Van P, Mao L, Fogarty A, Rawstorne P, Crawford J, Prestage G, et al.
Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. *AIDS* 2005; 19: 179-184

26. Hasse B, Ledergerber B, Hirschel B, Vernazza P, Glass TR, Jeannin A, *et al.* Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. *Clinical Infectious Diseases* 2010; 51: 1314–1322

27. Seng R, Rolland M, Beck-Wirth G, Souala F, Deveau C, Delfraissy J, *et al.* Trends in unsafe sex and influence of viral load among patients followed since primary HIV-infection, 2000-2009. *AIDS* 2011; 25: 977-988

28. Lampe FC, Daskalopoulou M, Phillips AN, Speakman A, Johnson MA for the ASTRA Study Group. Sexual behaviour among people with HIV according to self-reported antiretroviral treatment and viral load status. *AIDS* 2016; 30: 1745-1759

29. Doyle JS, Degenhardt L, Pedrana AE, McBryde ES, Guy RJ, Stoove MA, Weaver ER, Grulich AE, Lo Y, Hellard ME. Effects of HIV antiretroviral therapy on sexual and injecting risk-taking behaviour: a systematic review and meta-analysis. *Clin Infect Dis* 2014; 59: 1483-1494

30. Desquilbet L, Deveau C, Goujard C, Hubert JB, Derouineau J, Meyer L. Increase in at-risk sexual behaviour among HIV-1-infected patients followed in the French PRIMO cohort. *AIDS* 2002; 16:2329–2333.

31. Bouhnik AD, Moatti JP, Vlahov D, Gallais H, Dellamonica P, Obadia Y. Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users. *J Epidemiol Community Health* 2002; 56:349–353.

32. Crepaz N, Hart TA, Marks G. HAART and sexual risk behaviour: a meta-analytic review. *JAMA* 2004; 292: 224-236

33. Kozal MJ, Amico KR, Chiarella J, Schreibman T, Cornman D, Fisher W, *et al.* Antiretroviral resistance and high-risk transmission behavior among HIV-positive
patients in clinical care. *AIDS* 2004; 18: 2185–2189

34. Elford J, Ibrahim F, Bukutu C, Anderson J. Sexual behaviour of people living with HIV in London: implications for HIV transmission. *AIDS* 2007; 21(Suppl 1):S63–70.

35. Stephenson JM, Imrie J, Davis MM, Mercer C, Black S, Copas AJ, *et al.* Is use of antiretroviral therapy among homosexual men associated with increased risk of transmission of HIV infection? *Sex Transm Infect* 2003; 79: 7-10.

36. Glass TR, Young J, Vernazza PL, Rickenbach M, Weber R, Cavassini M, *et al.* Is unsafe sexual behaviour increasing among HIV-infected individuals? *AIDS* 2004; 18: 1707–1714

37. Morin SF, Myers JJ, Shade SB, Koester K, Maiorana A, Dawson Rose C. Predicting HIV transmission risk among HIV-infected patients seen in clinical settings. *AIDS Behav* 2007; 11: S6-S16

38. Golin C, Marks G, Wright J, Gerovich M, Tien H, Patel SN, *et al.* Psychosocial characteristics and sexual behaviours of people in care for HIV infection: an examination of men who have sex with men, heterosexual men and women. *AIDS Behav* 2009; 13: 1129-1142

39. Kalichman SC, Cherry C, White D, Jones M, Grebler T, Kalichiman M, *et al.* Sexual HIV transmission and antiretroviral therapy: a prospective cohort study of behavioural risks factors among men and women living with HIV/AIDS. *Ann Behav Med* 2011: 42: 111-119

40. Harding R, Cluas C, Lampe FC, Norwood S, Leake-Date H, Fisher M, *et al.* Behavioural surveillance study: sexual risk taking behaviour in UK HIV outpatients. *AIDS Behav* 2012; 16:1708-1715

41. Braga Cunha C, Brandini De Boni R, Cotrim Guimaraes MR, Yanavich C, Goncalves Veloso V, Ismerio Moreira R, *et al.* Unprotected sex among men who have sex with
me living with HIV in Brazil: a cross-sectional study in Rio de Janeiro. *BMC Public Health* 2014; 14: 379

42. Durham MD, Buchacz K, Richardson J, Yang D, Wood K, Yangco B, et al and the HOPS investigators. Sexual risk behavior and viremia among men who have sex with men in the HIV outpatients study, United States, 2007-2010. *JAIDS* 2013; 63: 372-378

43. Harding R, Eisencllas JH, Strauss R, Sherr L, De Lima L, Cahn P. Sexual risk-taking behaviour among HIV outpatients in Argentina. *AIDS Care* 2013; 25: 1077-1082

44. Mattson CL, Freedman M, Fagan JL, Frazier EL, Beer L, Huang P, et al for the Medical Monitoring Project. Sexual risk behaviour and viral suppression among HIV-infected adults receiving medical care in the United States. *AIDS* 2014; 28: 1203-1211

45. Siqueira Julio R, Khalili Friedman R, Cunha CB, Brandini De Boni R, Wagner Cardoso S, Torres T, Almeida Alves C, Castro C, Martinez Fernandes N, Veloso VG, Grinsztejn B. Unprotected sexual practices among men who have sex with women and men who have sex with men living with HIV/AIDS in Rio de Janeiro. *Arch Sex Behav* 2015; 44: 357-365

46. Champenois K, Seng R, Persoz A, Essat A, Gaud C, Laureillard D, Robineau O, Duvivier C, Yazdanpanad Y, Goujard C, Meyer L for the ANRS PRIMNO Cohort Study Group. Calendar trends in sexual behaviour in a cohort of HIV-infected MSM at the era of treatment as prevention of HIV infection. *AIDS* 2018; 32: 1871-1879

47. Burman W, Grund B, Neuhaus JN, Douglas J Jr, Friedland G, Telzak E, et al. Episodic Antiretroviral Therapy Increases HIV Transmission Risk Compared With Continuous Therapy: Results of a Randomized Controlled Trial. *J Acquir Immune Defic Syndr* 2008; 49: 142-150.

48. Jean K, Gabillard D, Moh R, Danel C, Fassassi R, Desgrees-du-Lou A, Eholie S, Lert F, Anglaret X, Dray-Spira R. Effect of early antiretroviral therapy on sexual
behaviours and HIV transmission risk among adults with diverse heterosexual partnership statuses in Cote d’Ivoire. *J Infect Dis* 2014; 209: 431-44

49. Daskalopoulou M, Rodger AJ, Phillips AN, Sherr L, Elford J et al. Condomless sex in HIV-diagnosed men who have sex with men in the UK: prevalence, correlates, and implications for HIV transmission. *Sex Trans Infect* 2017; 93: 590-598

50. AJ Rodger, FC Lampe, AE Grulich et al. Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. *HIV Medicine* (2015), 16 (Suppl. 1), 64–76

51. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. *Lancet* 2008; 372: 314-20

52. Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. *AIDS* 2014; 28: 1509-19

53. Fox J, White PJ, Macdonald N et al. Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. *HIV Med* 2009; 10: 432–438.

54. Heijman T, Geskus RB, Davidovich U, Coutinho RA, Prins M, Stolte IG. Less decrease in risk behaviour from pre-HIV to post-HIV seroconversion among MSM in the combination antiretroviral therapy era compared with the pre-combination antiretroviral therapy era. *AIDS* 2012; 26: 489–495.
Table 1. Demographic and HIV-related factors at baseline, according to gender/sexual orientation, among 4572 participants included in the analysis*

|                      | MSM (N=2562) | Heterosexual men (N=788) | Women (N=1222) |
|----------------------|--------------|--------------------------|----------------|
|                      | n            | %                        | n             | %            |
| **Age group (years)**|              |                          |               |              |
| <30                  | 1279         | 34.2                     | 127           | 16.1         | 275          | 22.5           |
| 30-39                | 1559         | 33.7                     | 268           | 34.0         | 429          | 35.1           |
| 40-49                | 1192         | 24.0                     | 251           | 31.9         | 327          | 26.8           |
| ≥50                  | 542          | 8.2                      | 142           | 18.0         | 191          | 15.6           |
| **Race**             |              |                          |               |              |
| White                | 2034         | 61.9                     | 262           | 33.2         | 185          | 15.1           |
| Black                | 1381         | 9.6                      | 360           | 45.7         | 775          | 63.4           |
| Hispanic             | 616          | 18.1                     | 58            | 7.4          | 94           | 7.7            |
| Asian                | 380          | 6.6                      | 77            | 9.8          | 133          | 15.1           |
| Other                | 161          | 3.7                      | 31            | 3.9          | 35           | 2.9            |
| **Region**           |              |                          |               |              |
| Europe/Israel        | 1498         | 45.3                     | 202           | 25.6         | 135          | 11.1           |
| S & Cent America     | 1155         | 32.5                     | 150           | 19.0         | 173          | 14.2           |
| Africa               | 978          | 1.0                      | 278           | 35.3         | 675          | 55.2           |
| North America        | 489          | 11.8                     | 82            | 10.4         | 105          | 8.6            |
| Asia                 | 348          | 5.7                      | 71            | 9.0          | 130          | 10.6           |
| Oceania              | 104          | 3.7                      | 5             | 0.6          | 4            | 0.3            |
| **Year randomised**  |              |                          |               |              |
| 2009-2010            | 978          | 26.1                     | 152           | 19.3         | 158          | 12.9           |
| 2011                 | 868          | 23.2                     | 125           | 15.9         | 150          | 12.3           |
| 2012                 | 1515         | 29.7                     | 274           | 34.8         | 479          | 39.2           |
| 2013                 | 1211         | 31.0                     | 237           | 30.1         | 435          | 35.6           |
| **Education**        |              |                          |               |              |
| Less high school     | 1357         | 10.4                     | 3345          | 43.8         | 746          | 61.1           |
| High school/equivalent| 988         | 21.4                     | 192           | 24.4         | 247          | 20.2           |
| Vocational/college   | 1191         | 34.6                     | 139           | 17.6         | 165          | 13.5           |
| University degree    | 1036         | 33.6                     | 112           | 14.2         | 64           | 5.2            |
| **Time since HIV diagnosis** | | | | | | |
| <3 months            | 915          | 23.2                     | 132           | 16.9         | 197          | 16.2           |
| 3-6 months           | 648          | 17.0                     | 92            | 11.8         | 126          | 10.4           |
| 6 months – 2 years   | 1424         | 32.8                     | 249           | 31.8         | 347          | 28.6           |
| 2 – 5 years          | 901          | 18.2                     | 169           | 21.6         | 274          | 22.6           |
| ≥5 years             | 632          | 8.8                      | 141           | 18.0         | 270          | 22.2           |
| **BL CD4 (cells/mm³)**|            |                          |               |              |
| 500-599              | 1451         | 33.9                     | 239           | 30.3         | 343          | 28.1           |
| 600-699              | 1426         | 32.9                     | 231           | 29.3         | 351          | 28.7           |
| ≥700                 | 1695         | 33.1                     | 318           | 40.4         | 528          | 43.2           |
| **BL VL (log c/mL)** |            |                          |               |              |
| <3                   | 580          | 7.4                      | 118           | 15.0         | 272          | 22.3           |
| 3-3.9                | 463          | 30.1                     | 238           | 30.2         | 455          | 37.3           |
| 4-4.9                | 2045         | 49.8                     | 348           | 44.2         | 423          | 34.7           |
| ≥5                   | 476          | 12.6                     | 84            | 10.7         | 69           | 5.7            |

*112 of 4684 randomised participants were not included in the sub-study as they did not complete the transmission risk behavior questionnaire at any of the three follow-up time points (months 4, 12 and 24). ~Missing values: n=57 for time since diagnosis; n=8 for baseline VL. BL=baseline
Table 2. Completion of transmission risk behaviour questionnaire, prevalence of ART use and VL≤200c/mL, during follow-up by randomized arm and gender/sexual orientation

|               | MSM (N=2562) | Heterosexual men (N=788) | Women (N=1222) |
|---------------|--------------|--------------------------|----------------|
|               | IMM          | DEF          | IMM          | DEF          | IMM        | DEF        |
| Baseline     |              |              |              |              |            |            |
| N with TRB~   |              |              |              |              |            |            |
| On ART n (%) |              |              |              |              |            |            |
| VL*≤200c/mL  |              |              |              |              |            |            |
| n (%)        | 1260 (4.9%) | 35 (2.8%)  | 1254 (4.2%) | 33 (2.6%)  | 594 (4.9%) | 615 (4.9%) |
| 4 months     |              |              |              |              |            |            |
| N with TRB~   |              |              |              |              |            |            |
| On ART n (%) |              |              |              |              |            |            |
| VL*≤200c/mL  |              |              |              |              |            |            |
| n (%)        | 1237 (4.8%) | 64 (5.4%)  | 1197 (5.0%) | 70 (5.9%)  | 588 (4.8%) | 612 (4.8%) |
| 12 months    |              |              |              |              |            |            |
| N with TRB~   |              |              |              |              |            |            |
| On ART n (%) |              |              |              |              |            |            |
| VL*≤200c/mL  |              |              |              |              |            |            |
| n (%)        | 1236 (4.8%) | 205 (17.3%) | 1187 (7.5%) | 198 (16.7%) | 583 (4.8%) | 586 (4.8%) |
| 24 months    |              |              |              |              |            |            |
| N with TRB~   |              |              |              |              |            |            |
| On ART n (%) |              |              |              |              |            |            |
| VL*≤200c/mL  |              |              |              |              |            |            |
| n (%)        | 1088 (4.2%) | 416 (39.3%) | 1058 (5.2%) | 401 (37.9%) | 452 (3.7%) | 447 (3.5%) |

~TRB=transmission risk behaviour questionnaire. ART status (on/off ART) determined at the date of the relevant TRB CRF
*VL is the latest VL up to the date of the relevant TRB CRF. VL missing for 5 MSM and 3 women at baseline
Table 3. Sexual behaviour and transmission risk beliefs, at baseline and during follow-up (months 4, 12, 24, 36) according to randomised arm, among MSM and heterosexual men and women

**(A): MSM**

| Sexual behaviour | ARM * | Baseline | Baseline 2 | 4 months | 12 months | 24 months |
|------------------|-------|----------|------------|----------|-----------|-----------|
|                  | N     | % (n)    | N          | % (n)    | N         | % (n)     | N         | % (n)    |
| ≥1 CLS partner   | IMM   | 107      | 39.3 (422) | 78       | 35.8 (281) | 114       | 27.6 (315) | 120       | 29.9 (360) | 108       | 33.9 (368) |
|                  | DEF   | 107      | 39.1 (419) | 80       | 36.6 (294) | 111       | 29.2 (326) | 115       | 31.9 (367) | 105       | 33.7 (355) |
| ≥2 CLS partners  | IMM   | 107      | 16.9 (182) | 78       | 16.7 (131) | 114       | 11.0 (126) | 120       | 12.1 (146) | 108       | 13.6 (148) |
|                  | DEF   | 107      | 16.2 (174) | 80       | 15.9 (128) | 111       | 11.2 (125) | 115       | 13.0 (150) | 105       | 12.7 (134) |
| ≥3 CLS partners  | IMM   | 107      | 8.6 (92)   | 78       | 8.5 (67)   | 114       | 5.3 (60)   | 120       | 5.7 (69)   | 108       | 5.7 (69)   |
|                  | DEF   | 107      | 8.1 (87)   | 80       | 8.2 (66)   | 111       | 4.6 (51)   | 115       | 6.6 (76)   | 105       | 6.5 (62)   |
| ≥1 CLS-D partner | IMM   | 126      | 19.7 (248) | 95       | 14.9 (142) | 123       | 11.7 (145) | 123       | 12.6 (156) | 108       | 16.3 (177) |
|                  | DEF   | 125      | 20.0 (251) | 97       | 16.5 (161) | 119       | 13.0 (155) | 118       | 13.1 (155) | 105       | 14.8 (157) |
| ≥2 CLS-D partners| IMM   | 107      | 7.6 (83)   | 78       | 6.9 (54)   | 114       | 4.6 (52)   | 120       | 4.6 (55)   | 108       | 6.2 (67)   |
|                  | DEF   | 107      | 7.6 (82)   | 80       | 6.5 (52)   | 111       | 5.6 (62)   | 115       | 5.7 (65)   | 105       | 5.8 (61)   |
| ≥3 CLS-D partners| IMM   | 107      | 3.6 (39)   | 78       | 3.4 (27)   | 114       | 1.7 (19)   | 120       | 1.9 (23)   | 108       | 2.4 (26)   |
|                  | DEF   | 107      | 3.3 (35)   | 80       | 3.0 (24)   | 111       | 2.0 (22)   | 115       | 2.5 (29)   | 105       | 2.9 (31)   |
| ≥2 times CLS-D   | IMM   | 107      | 13.9 (149) | 78       | 10.7 (84)  | 114       | 7.2 (82)   | 120       | 8.3 (100)  | 108       | 11.1 (120) |
|                  | DEF   | 107      | 13.8 (148) | 80       | 10.6 (85)  | 111       | 8.9 (100)  | 115       | 9.4 (108)  | 105       | 10.0 (105) |
| >10 times CLS-D  | IMM   | 107      | 3.9 (42)   | 78       | 2.8 (22)   | 114       | 1.7 (19)   | 120       | 2.4 (29)   | 108       | 2.4 (26)   |
|                  | DEF   | 107      | 3.1 (33)   | 80       | 1.9 (15)   | 111       | 1.4 (16)   | 115       | 1.7 (19)   | 105       | 2.3 (24)   |

*p = 0.41  p = 0.28  p = 0.91

*p = 0.91  p = 0.50  p = 0.53

*p = 0.45  p = 0.37  p = 0.42

*p = 0.36  p = 0.75  p = 0.36

*p = 0.28  p = 0.23  p = 0.71

*p = 0.59  p = 0.31  p = 0.43

*p = 0.14  p = 0.35  p = 0.41

*p = 0.65  p = 0.20  p = 0.86
### Insertive CLS-D with ejaculation

|        | IMM | DEF |
|--------|-----|-----|
| N      | 107 | 107 |
| Mean (SD), Median | 8.5 (91), 6.5 (51) | 8.3 (89), 4.7 (38) |

|        | IMM | DEF |
|--------|-----|-----|
| N      | 126 | 125 |
| Mean (SD), Median | 19.7 (248), 14.9 (142) | 20.0 (251), 16.5 (161) |

|        | IMM | DEF |
|--------|-----|-----|
| N      | 126 | 125 |
| Mean (SD), Median | 11.7 (145), 13.0 (155) | 11.0 (130), 11.0 (130) |

### ≥1 CLS-D-HIV-risk partner

|        | IMM | DEF |
|--------|-----|-----|
| N      | 107 | 107 |
| Mean (SD), Median | 4.5 (54), 4.2 (48) | 4.0 (3), 3.7 (42) |

|        | IMM | DEF |
|--------|-----|-----|
| N      | 126 | 125 |
| Mean (SD), Median | 4.2 (58), 4.5 (54) | 4.5 (58), 4.5 (58) |

### Believe that UVL greatly reduces transmission risk

|        | IMM | DEF |
|--------|-----|-----|
| N      | 104 | 104 |
| Mean (SD), Median | 37.9 (398), 42.6 (470) | 36.8 (386), 37.9 (413) |

|        | IMM | DEF |
|--------|-----|-----|
| N      | 104 | 104 |
| Mean (SD), Median | 48.1 (568), 40.4 (452) | 52.9 (559), 46.8 (481) |

### Number of CLS-D acts among subset with baseline CLS-D

|        | IMM | DEF |
|--------|-----|-----|
| N      | 12  | 13  |
| Mean (SD), Median | 9.0 (14.5), 3.3 (7.6) | 6.1 (7.6), 3.3 (5.6) |

|        | IMM | DEF |
|--------|-----|-----|
| N      | 128 | 140 |
| Mean (SD), Median | 4.5 (8.8), 3.2 (6.7) | 4.4 (10.3), 2.6 (5.2) |

(B): Heterosexual men and women

### Sexual behaviour

|         | ARM * | Baseline | Baseline 2<sup>2</sup> | 4 months | 12 months | 24 months |
|---------|-------|----------|-------------------------|----------|-----------|-----------|
|         | N     | % (n)    | N     | % (n)    | N     | % (n)    | N     | % (n)    |
| ≥1 CLS partner | IMM  | 882 | 26.2 (231) | 73 9 | 25.0 (185) | 896 | 20.0 (179) | 91 0 | 19.3 (176) |
|         | DEF  | 928 | 26.6 (247) | 75 6 | 24.9 (188) | 946 | 21.9 (207) | 93 6 | 21.3 (199) |

|         | IMM  | 966 | 13.4 (129) | 81 7 | 12.1 (99) | 948 | 8.1 (77) | 93 4 | 10.8 (101) |
|         | DEF  | 928 | 2.3 (21) | 75 6 | 1.9 (14) | 946 | 1.5 (14) | 93 6 | 1.1 (10) |

|         | IMM  | 966 | 13.4 (129) | 81 7 | 12.1 (99) | 948 | 8.1 (77) | 93 4 | 10.8 (101) |
|         | DEF  | 928 | 2.3 (21) | 75 6 | 1.9 (14) | 946 | 1.5 (14) | 93 6 | 1.1 (10) |
|                | IMM | DEF |                | IMM | DEF |                | IMM | DEF |                |
|----------------|-----|-----|----------------|-----|-----|----------------|-----|-----|----------------|
| ≥2 CLS-D       | 882 | 928 | partners      | 1.3 | 1.6 | 1.2 (9)        | 896 | 946 | 0.6 (5)       |
|                | 91  | 93  | 0.6 (5)       | 73  | 75  | 1.2 (9)        | 96  | 93  | 0.6 (5)       |
|                | 84  | 5   | 0.4 (4)       | 84  | 5   | 0.4 (4)       | 84  | 5   | 0.4 (4)       |
|                | 84  | 5   | 0.8 (5)       | 84  | 5   | 0.8 (5)       | 84  | 5   | 0.8 (5)       |
|                | p=0.60 | p=0.062 | p=0.007   | p=0.83 | p=0.785(F) | p=0.75 |
| ≥2 times CLS-D | IMM | DEF |                | 9.8 | 8.4 | 8.1 (60)       | 896 | 946 | 5.8 (55)     |
|                | 91  | 93  | 1.2 (9)       | 96  | 93  | 0.6 (5)       | 73  | 75  | 0.8 (5)       |
|                | 84  | 5   | 0.4 (4)       | 84  | 5   | 0.4 (4)       | 84  | 5   | 0.4 (4)       |
|                | 84  | 5   | 0.8 (5)       | 84  | 5   | 0.8 (5)       | 84  | 5   | 0.8 (5)       |
|                | p=0.000 | p=0.73 | p=0.006   | p=0.93 | p<0.001 | p=0.000 |
| Insertive     | IMM | DEF | CLS-D with    | 9.3 | 7.4 | 6.9 (19)       | 335 | 367 | 5.7 (21)     |
|                | 93  | 367 | ejaculation   | 33  | 367 | 4.9 (18)       | 73  | 73  | 2.4 (7)      |
|                | 876 | 367 | (men only)    | 84  | 367 | 6.0 (18)       | 73  | 73  | 2.4 (7)      |
|                | p=0.046 | p=0.089 | p=0.008   | p=0.93 | p<0.001 | p=0.000 |
| ≥1 CLS-D-      | IMM | DEF | HIV-risk      | 13.4| 11.8| 12.1 (99)      | 948 | 100 | 8.1 (77)    |
| HIV-risk       | 91  | 100 | partner*     | 93  | 100 | 8.1 (77)      | 96  | 100 | 8.1 (77)    |
| partner*       | 96  | 100 | 0.6 (6)      | 96  | 100 | 0.6 (6)       | 96  | 100 | 0.6 (6)      |
|                | 84  | 5   | 4.9 (18)      | 84  | 5   | 4.9 (18)      | 84  | 5   | 4.9 (18)      |
|                | p=0.60 | p<0.001  | p<0.008   | p=0.60 | p<0.001  | p<0.008 |
| Believe that   | IMM | DEF | UVL greatly    | 31.6| 31.2| 12.1 (99)      | 948 | 100 | 8.1 (77)    |
| reduces        | 91  | 100 | reduces       | 93  | 100 | 8.1 (77)      | 96  | 100 | 8.1 (77)    |
| transmissio    | 96  | 100 | transmissio   | 96  | 100 | 8.1 (77)      | 96  | 100 | 8.1 (77)    |
| n risk         | 84  | 5   | 0.6 (6)       | 84  | 5   | 0.6 (6)       | 84  | 5   | 0.6 (6)       |
|                | p=0.001 | p<0.001  | p<0.001   | p=0.01 | p<0.01  | p<0.01 |
| Number of      | IMM | DEF | CLS-D acts    | 7.7 | 6.4 | 2.7 (6.1)      | 92  | 92  | 3.5 (8.7)    |
| acts among     | 90  | 78  | subset with   | 90  | 78  | 4.1 (8.3)      | 70  | 78  | 2.6 (8.3)    |
| baseline       | 6   | 6   | baseline      | 6   | 6   | 0              | 6   | 6   | 0              |
| CLS-D©         | 92  | 78  | 0              | 92  | 78  | 0              | 92  | 78  | 0              |
|                | p=0.01 | p=0.049  | p=0.099   | p=0.01 | p<0.01  | p<0.01 |

*Randomised arm. IMM=immediate ART, DEF=deferred ART
CLS=All condomless sex.
CLS-D = Condomless sex with HIV negative (or unknown status) partner(s).
CLS-D-HIV-risk= HIV transmission risk sex defined as CLS-D plus at least one of: not on ART; started ART <6 months ago; most recent VL>200c/mL; no VL in last 6 months

Baseline 2 estimates exclude those diagnosed less than 3 months before completing the baseline questionnaire, who may be reporting pre-diagnosis sexual behavior.
P values by Chi-squared tests or Fisher’s exact test (F), or Mann-Whitney U tests for CLS-D acts. p value for change from baseline in number of CLS-D acts in subset.
For each analysis denominators are all participants who submitted a transmission risk behavior questionnaire at that time point.
# Denominators are larger for CLS-D and CLS-D-HIV-risk as these measures could be derived from both versions of the risk behavior questionnaire; other measures could be derived only from the updated version.
Missing values: For binary measures of CLS, CLS-D, CLS-D-HIV-risk, among those who completed the relevant transmission risk behaviour questionnaire, missing data were assumed to be the absence of the behaviour (<5% cases). For transmission risk beliefs, missing data were excluded. For number of CLS-D acts see below.
~ Number of CLS-D acts was approximated from grouped data as follows: 2-10 times approximated as 6; 11-30 times approximated as 20; More than 30 times approximated as 40.
Number of CLS-D partners was approximated from grouped data as follows: 3-5 women approximated as 4; more than 5 women approximated as 8.
For those who had CLS-D, if number of CLS-D acts was missing or was less than the number of CLS-D partners, the value for number of CLS-D partners was used, if this was missing, number of CLS-D partners and number of CLS-D acts was set to one.
£ Subset is those who reported CLS-D at baseline and who had been diagnosed with HIV for at least 3 months at baseline.
Figure 1. Effect of randomised group on CLS-D at month 12, according to baseline factors among MSM and heterosexual men and women

CLS-D=condomless sex with HIV serodifferent (negative or unknown) status partner

Odds ratio from logistic regression model

*p value from test of interaction between each baseline factor and randomised group

~Low/middle income (Africa; Asia; Central/South America); High income (Europe/Israel; North America; Oceania)

A) MSM

B) Heterosexual men and women
Figure 2. Prevalence of CLS-D in the past three months by time point and randomised arm among MSM, and heterosexual men and women: a) CLS-D; b) CLS; c) CLS-D-HIV-risk

*Baseline estimates are also shown excluding participants who had been diagnosed with HIV for less than 3 months.

For denominators by time point and p values comparing randomised arms, see Table 3.

CLS-D=condomless sex with HIV serodifferent (negative or unknown) status partner

CLS=condomless sex

CLS-D-HIV-risk=HIV-transmission risk sex

MSM= men who have sex with men; HET= heterosexual men and women IMM=immediate arm; DEF=deferred arm